Zepbound versus Wegovy
In this episode of the Docs Who Lift podcast, Dr. Spencer Nadolsky and Dr. Karl discuss the latest findings from the SURMOUNT-5 on Zepbound (tirzepatide) vs. Wegovy (semaglutide,) two leading medications for weight loss and type 2 diabetes. They explore the efficacy, safety, and cost-effectiveness of these drugs, highlighting the significant weight loss outcomes associated with tirzepatide compared to semaglutide. The conversation also delves into the importance of patient stewardship in prescribing these medications, the impact of gender differences on weight loss results, and the need for more affordable options in the market.
Audio is streamed directly from the publisher (injector.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
- Tirzepatide is more effective for weight loss than semaglutide.
- Cost-effectiveness is crucial in prescribing weight loss medications.
- Patients with severe obesity should receive more expensive medications for better outcomes.
- Both medications show significant benefits for obesity-related conditions.
- Long-term studies indicate sustained weight loss with both drugs.
- Gender differences affect weight loss outcomes with these medications.
- Safety profiles show tirzepatide may be better tolerated than semaglutide.
- The need for affordable drug pricing is emphasized.
- Clinical benefits extend beyond weight loss to include metabolic health.
- Future studies are needed to confirm cardiovascular benefits of tirzepatide.
Click here to join Dr. Spencer's new online clinic
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.